AWARD NUMBER: W81XWH-13-1-0303

TITLE:
Characterizing and Targeting Bone Marrow-Derived Inflammatory Cells in Driving the Malignancy and Progression of Childhood Astrocytic Brain Tumors

PRINCIPAL INVESTIGATOR: Yujie Huang Ph.D.

CONTRACTING ORGANIZATION:
Cornell University, Weill Cornell Medical College
New York, NY 10065-4805

REPORT DATE: September 2015

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
In this study, we have utilized glioma patients along with two unique murine glioma models: RCAS glioma model and G1261 model to study various lineages of BMDCs during different stages of glial tumors. Importantly, we identified the unique the population VEGFR2+MDSCs in both patients and mice, which might be used as a surrogate marker for glioma diagnosis and prognosis in future. We have validated the changes of myeloid lineage and endothelial lineages during the progression of gliomas, and We observed bone marrow derived mesenchymal stem cells have only minimal effort on tumor progression. We have created inducible VEGFR2 knockout system in RCAS-tva model. We demonstrated that bone marrow derived VEGFR2 signaling plays an important role in myeloid differentiation, and infiltration into tumor tissues. Deficiency of VEGFR2 in BMDCs led to impairment of tumor associated myeloid cells and delayed progression of low-grade glioma. Primary tumor up-regulates VEGFR2 in BMDCs through ID2/E2A pathway. All of these findings may have implications to suppress the switch of low-grade to high-grade transformation, and predict the long-term survival.

Glioma, Pediatric, bone-marrow-derived-cells, endothelial, mesenchymal, myeloid, hematopoietic, differentiation, malignant, transformation, VEGFR2, ID2.
# Table of Contents

1. Introduction..................................................................................2
2. Keywords...................................................................................3
3. Overall Project Summary...........................................................4
4. Key Research Accomplishments...............................................20
5. Conclusion................................................................................21
7. Inventions, Patents and Licenses...............................................22
8. Reportable Outcomes.................................................................22
9. Other Achievements.................................................................22
10. References...............................................................................23
11. Training & Professional Development ......................................24
12. Appendices ............................................................................25
1. Introduction

Brain tumors are most frequent solid cancer among all kinds of childhood cancer. Heterogeneity, invasiveness, and complex microenvironment are making therapies as well as research on astrocytic brain tumors particularly challenging. Low-grade gliomas are curable and most patients could live without further progression and severe condition for many years. However, once the glioma progresses to high grade, the quality of life and survival of patients are very poor. Based on previous work, we hypothesized that the bone marrow-derived cells (BMDCs) could serve as a mediator of transition of low grade to high-grade tumors. The proposed project aims to characterize the various lineages of glioma-associated BMDCs including hematopoietic, endothelial, and mesenchymal lineages in both low grade and high grade stages of glioma. Studying the effect on glioma transition from low grade to high grade by depleting distinct populations of bone marrow derived inflammatory cells including monocyte, granulocytes, endothelial progenitors, and mesenchymal progenitors. Dissecting molecular mechanisms/signaling of differentiation of glioma-associated BMDCs, and screening the key factors or targets through the entire regulatory pathway. It would contribute to develop therapeutic strategies to target a specific population of BMDCs and their subsequent recruitment, in order to suppress the malignant transformation of gliomas. In this project, we have initiated the study of BMDCs with RCAS and GL261 murine glioma models as well as glioma patients. We also used transgenic tools to deplete certain populations of BMDCs to study functional contribution of BMDCs for glioma progression.
2. Keywords

Glioma, Pediatric, bone-marrow-derived-cells, endothelial, mesenchymal, myeloid, hematopoietic, differentiation, malignant, transformation, Inhibitor of DNA binding protein.
3. Overall Project Summary

The project focuses on studying the microenvironment and functions of bone marrow derived cells within pediatric astrocytic tumor. In this study, two major glioma models will be used to investigate the role of BMDCs primarily. One is a transgenic mouse using the RCAS/Tv-a system created by Holland and Varmus that develops low-grade gliomas which progress to high-grade tumors over the course of twelve weeks. The other model is syngeneic orthotopic glioma model. Gl261, a C57/Bl6 derived glioma cell line with different markers such as GFP or luciferase, was intracranial injected to C57/Bl6 mice to create allograft glioma. In addition, xenograft models with human glioma cell lines are also utilized. Furthermore, we also have used glioma patients’ blood samples to analyze various lineages of BMDCs.

Task 1. Charactering the various lineages of glioma associated BMDCs including hematopoietic, endothelial, and mesenchymal lineages in both low grade and high gradestages of glioma. (90% complete)

We have analyzed the myeloid lineage and endothelial lineage of BMDCs in both patients’ blood samples and murine glioma models at low-grade or high-grade stage.

1a. Assess the frequency and absolute numbers of circulating BMDCs in glioma patients. Using flow-cytometry of hematopoietic, as well as endothelial and mesenchymal markers, we will investigate whether the frequency of HPCs, VEGFR2+ EPCs and CD105+ MSCs correlates with glioma transformation in patients. Human subjects involve this study will be radiographically-suspected or biopsy prove low-grade astrocytoma (WHO grade I and II) versus histology proven high grade gliomas (WHO grade III and IV). Blood samples will be collected at the time of diagnosis. Subjects selected for this study may be between 2 years and 16 years of age. We plan to enroll 160 human subjects, and quarterly enrollment is 20. The identifications of human subjects will not be accessible for research team, and only information of human subjects that research team is aware of is the patients’ diagnosis and diseases’ history.

Up to date, we have recruited 107 glioma patients with low-grade or high-grade glioma, plus 26 healthy volunteers as control into this study. Patients or healthy volunteers’ peripheral blood has been analyzed with various lineages makers as showed in the figures below:
Figure 1. Characterizing myeloid lineage of BMDCs in patients (CD11b, CD33, CD14, and CD16) by flow cytometry in peripheral of low-grade astrocytoma patients (LGA) vs glioblastoma patients (GBM).

Figure 2. IHC of CD11b (infiltrated myeloid cells) on archived paraffin embedded tumor tissue from low-grade astrocytoma patients (grade II) vs glioblastoma patients (grade IV).
Figure 3. Characterizing endothelial/myeloid lineage of BMDCs in patients by CD11b, KDR (VEGFR2) in peripheral of low-grade astrocytoma patients (LGA), glioblastoma patients (GBM), and healthy volunteers.

![Graph of Figure 3](image)

Figure 4. Statistic dots-plot on frequency of CD11b+/VEGFR2(KDR)+ cells out of total CD11b+ cells in patients with different stages of disease. Healthy donor served as a control. GI/GII vs healthy, One way ANOVA, P <0.001.

![Graph of Figure 4](image)

Figure 5. Grade II glioma patients were sub-divided into two groups, based on the frequency of CD11b+/KDR (VEGFR2)+ cells: KDR Hi and KDR Lo (cut-off, 1.0%). Kaplan-Meier curves for progression-free survival over 12 months are presented (27 subjects). P <0.01 by log-rank test.

![Graph of Figure 5](image)

During the study of BMDCs with glioma patients’ blood samples, we have found that the number of myeloid derived suppor cells (MDSCs) within myeloid lineage increased following the progression of diseases. The MDSCs are heterogeneous regarding the
expression of CD14/CD16, representing monocytic or granulocytic sub-lineages (Figure 1). While the tumor progressed, we also observed more infiltrated myeloid cells within tumor tissues (Figure 2). Interestingly, when we examine the expression of VEGFR2 to study endothelial lineage of BMDCs, we found the majority of VEGFR2 expressing cells are CD11b positive as showed in Figure 3. It suggested that there is overlap or interaction between myeloid lineage and endothelial lineage of BMDCs. Quantification of CD105+/C-kit+ BMDCs indicates no significant difference in MSCs from patients with low-grade patients vs high-grade patients. Therefore, we would focus on raveling the role of myeloid/endothelial lineage in glioma progression by following animal study.

Based on the analysis on large cohort of patients, we found that the number of CD11b+/KDR+ BMDCs have significant correlation with the pathological diagnosis of patients. The ratio of KDR+ myeloid cells was significantly higher in blood samples derived from patients with high-grade gliomas when compared with samples from patients with low-grade gliomas. Specifically, the levels of CD11b+KDR+ cells were higher in patients with WHO grade III or IV tumors than it is in patients with grade I tumors and healthy controls (Figure 4). Perhaps most striking is the apparent delineation of two distinct populations of patients, each with pathologically defined grade II astrocytoma. We sub-divided patients with grade II astrocytoma into two subgroups, those with high versus low CD11b+KDR+ values (cut-off of 1.0%). The clinical course and medical histories of the patients were closely followed over 12 months. Disease progression in patients with grade II glioma was assessed by MRI and through subsequent histological diagnoses of grade III or IV glioma. The progression-free survival of our cohort of grade II patients is shown in Fig. 2c. Patients with an elevated percentage of CD11b+KDR+ (KDR Hi) myeloid cells presented a significantly higher likelihood of tumor progression from fibrillary to anaplastic variants (Figure 5).

1b. Evaluate the frequency and number of the same BM-derived populations in blood, bone marrow and metastatic organs of murine models of glioma during low grade, transformation grade and high grade phases. Specifically, we will investigate the mobilization of HPCs, EPCs, and MSCs by flow cytometry.

We have analyzed the HPCs, EPCs, and MSCs in both RCAS and Gl261 murine glioma models. The 4-6 weeks post-injection of RCAS model were consider as the low-grade stage, and 6-9 weeks were considered high-grade stage. The Gl261 model was considered as high-grade glioma model.
We characterized the RCA-tva murine glioma model in our experimental setting, and figured out their low-grade stage and high-grade stage evidenced by MRI and histology. Additionally, we showed the RCAS mice with bone marrow transplantation have delayed progression of tumor, which is important for our next step of study.
Figure 8. The expression of VEGFR2 on BMDCs in Gl261 model. Upper panel of schematic model showed the VEGFR2-GFP knock in mice for studying expression pattern of VEGFR2. Lower panel of flowcytometry graphs indicate the expression VEGFR2 on CD11b+ or CD11b- population.

Figure 9. EPC in Gl261 glioma model. Flowcytometry graph of lineage negative CD144+ VEGFR2+ EPC in Gl261 tumor bearing mice.
We have studied the myeloid lineage and EPC with Gl261 glioma model. We observed that both VEGFR2+ myeloid cells and EPCs were elevated by Gl261 tumor, indicating potential interaction of BMDCs differentiation with primary glioma.

Task 2. Studying the effect on glioma transition from low grade to high grade by depleting distinct populations of bone marrow derived inflammatory cells including monocyte, granulocytes, endothelial progenitors, and mesenchymal progenitors. (90% complete)

We have set up all trans-genetic mice lines including ITGAM(CD11b)-DTR/EGFP mice, RosaCreERT2/PDGFRα–loxP/loxP mice, and RosaCreERT2/VEGFR2loxP/loxP mice in suitable genetic background for bone marrow transplantation experiments. We performed the lineage depletion experiments with ITGAM(CD11b)-DTR/EGFP and RosaCreERT2/VEGFR2loxP/loxP mice for myeloid or endothelial lineages in both RCAS and Gl261 tumor models.

2a. We plan to transplant the bone marrow from ITGAM(CD11b)-DTR/EGFP mice into the RCAS and Gl261 glioma models, and use diphtheria toxin to induce depletion of myeloid cells in this RCAS glioma model.

Figure 10. Competitive BMT showed that KDR knockout in bone marrow cells lead to deficiency of the differentiation of monocytic cells. Lethal dose irradiated C57/bl6 mice were transplanted with UBC-GFP/rosa26ERT2-cre/KDRfl/fl and rosa26ERT2-cre/KDRfl/+ bone marrow cells, and Gl261 tumors were implanted after bone marrow engraftment. (a) Peripheral white blood cells were analyzed on SSC and GFP by flow cytometry. The GFP+ and GFP- populations were gated for further analysis. CD11b vs GFP (b), Ly6C vs Ly6G (c).
We have developed the ITGAM(CD11b)-DTR/EGFP bone marrow transplanted mice and implanted mice with GL261 tumor after bone marrow was engrafted. We have tried to deplete the CD11b positive cells in tumor bearing mice once with 5 mice in each group. However, we only obtained approximately 10% deduction of CD11b cells compared with control group. In this case, we didn’t see effect on tumor growth. However, as Figure 10 showed, knockout KDR (VEGFR2) led to significant reduction of CD11b+ cells, among which Ly6 C+ cells were suppressed dramatically. In conclusion, knockout VEGFR2 has considerably effect on myeloid lineage, which is inconsistent co-expression VEGFR2 and CD11b in high-grade patients’ BMDCs samples. Accordingly, we have used VEGFR2 deficient model in the following study.

2b. Bone marrow from RosaCreERT2/VEGFR2loxP/loxP mice will be transplanted to both RCAS glioma and GL261 bearing mice to deplete endothelial lineage of bone marrow derived cells by knocking out the VEGFR2 gene. The total number of mice will be used is 30.

We have successfully knocked out VEGFR2 in both RCAS model and GL261 murine model. We have studied the effect of VEGFR2 deficiency on glioma progression.

As Figure 11 showed, we could obtain around 90% knocking out efficiency with our RosaCreERT2/VEGFR2loxP/loxP system, without affecting counts of blood cells (CBC) of mice.

Figure 11. Validation of depletion of VEGFR2 (KDR) allele in bone marrow cells. (a) Amplification of KDR+ or KDR- allele on bone marrow cells of mice bearing indicated genetic background. Tamoxifen was applied to mice one week before testing. Complete bloods count on mice with WT, KDR+/-, or KDR-/- bone marrow (b) Red blood cells, (c) white blood cells, and (d) Platelets.
When we knockout VEGFR2 from BMDCs in Gl261 models, we observed that tumor progression were suppressed as showed in figure 12. In the tumor tissue, we found much less tumor associated myeloid cells (CD11b+) in the VEGFR2 KO group compared with control group (Figure 13). With RCAS system, we found the similar phenotype, after we performed the bone marrow transplantation and induced VEGFR2 knockout, we observed that tumor progression were delayed and median survival time (MST) was significantly elongated (Figure 14).

Figure 12. Knocking-out VEGFR2 (KDR) in BMDCs suppress Gl261 tumor growth, tumor-associated myeloid cells, and vasculatures. Chimeric C57/bl6 mice transplanted with rosa26ERT2-cre/KDRfl/fl bone marrow cells (labeled as BM-KDR KO, and BM-KDR control is rosa26ERT2-cre/KDRfl/+ ) were implanted with luciferase labeled-Gl261 tumors intracranially. Tamoxifen were applied at day 3 post- implantation. The tumors were monitored by bioluminescence. The quantification of bioluminescence based tumor growth.

Figure 13. Immuno-staining of vascular basement (Collagen IV) and myeloid cells (CD11b) in the Gl261 tumors from each group. Scale bar, 20 µm. The number of CD11b cells in tumor core or tumor margin was quantified.
Figure 14. Knocking-out VEGFR2 (KDR) in BMDCs suppress spontaneous malignant transformation of RCAS gliomas. (a) Flow chart of experimental design. Oncogenes were transduced to P0-P2 pups in the beginning. Mice received lethal dose irradiation and received bone marrow transplantation at week 2, and then tamoxifen was applied to mice at week 5 to induce the ablation of target gene. Tumors were monitored by MRI over the process. (b) Kaplan-Meier symptom free survival curve for RCAS mice transplanted with rosa26ERT2-cre/KDRfl/fl bone marrow cells (BM-KDR KO), rosa26ERT2-cre/KDRfl/fl bone marrow cells (BM-KDR Con), or without irradiation/transplantation (W/O BMT).

Figure 15. At weeks 6, week 9, and week 12, tumors in each group of mice were assessed and graded based on their MRI and further confirmation with histology. N=19~26.

We compared brain tumors in RCAS/tva mice at weeks 6, 9 and 12, utilizing MRI followed by histological examination (Figure 15). Knocking out KDR in BMDCs significantly delayed the malignant transformation of low-grade glioma. By week 9, 60% of RCAS/tva mice transplanted with control R26CreERKDRfl/+ bone marrow developed high-grade tumors, which had typical malignant features, including robust gadolinium
enhancement on MRI, pseudopalisading necrosis, and microvascular proliferation. In contrast, tumors in 70% of RCAS/tva mice transplanted with R26CreERKDRfi/fl bone marrow remained in the low-grade stage without signs of malignant transformation at week.

2c. Bone marrow cells from RosaCreERT2/PDGFRαloxP/loxP mice will be transplanted to each genetic and orthotopic glioma generating mice. PDGFRα is expressed on bone marrow derived mesenchymal stem cells and PDGF-PDGFRα signal axis is very critical for maintenance of mesenchymal lineage. By knocking out PDGFRα gene, we will study the influence of defection of mesenchymal differentiation on the progression of low-grade glioma. The total number of mice will be used is 30.

We have completed the crossing donor RosaCreERT2/PDGFRαloxP/loxP mice, and the bone marrow transplantation experiments along with tumor study are ongoing. As study has showed, Deletion of PDGFRα gene in BMDCs have no significant influence on development of Gl261 tumor in mice brain. Interestingly, we observed that tumor did growly slower and in RosaCreERT2/PDGFRαloxP/loxP mice compared with control mice. It suggests that residential PDGFRα+ cells play more important role in tumor progression than bone marrow derived PDGFR+ cells. (Figure 16)

Figure 16. Knocking out PDGFRα in stromal cells inhibits glioma progression. Luciferase-Gl261 cells were intracranially injected into RosaCre-ERT2/PDGFRα fl/fl mice and RosaCre-ERT2/PDGFRα+/+ mice. A, tumor burden is represented by photon flux intensity. P < 0.05. B, precontrast and postcontrast T1-weighted MRIs were performed on each group at day 15. Arrows, enhancing tumor. Tumor volume quantification is demonstrated. P < 0.01. C, vWF was stained in the tumor periphery and within the tumor of each group (left and middle panels). Collagen IV was stained in each group (right). Scale bar, 50 µm. Vessel diameters were quantified. P < 0.05.
Task 3. Dissecting molecular mechanism/signaling of differentiation of glioma associated BMDCs, and screening the key factors or targets through the entire regulatory pathway. (60% complete)

We will proceed to study which genes in certain lineages of BMDCs could play a critical role in promoting the invasion of glioma. We will isolate specific population from BMDCs from the tumor tissue, blood, and bone marrow. Then we utilize microarray/next generation sequencing, antibody array, LC-TOF-TOF to detect gene and protein expression. To determine the functional contribution of certain genes of interest, or certain subpopulation of BMDCs, we plan to utilize a series of in vitro/in vivo experiments, including basement invasion assay and knock specific genes bone marrow cells and then transplant them into glioma producing mice, to elucidate their specific roles in promoting invasion of glioma cells and infiltration of glioma. Total number of mice will be used for this study is 30.

We have been working on optimizing sorting different lineages of BMDCs by FACS or MACS and tested a few samples by RNA sequencing. The data suggested that ID2/VEGF2 signaling was playing important role in myeloid differentiation.

In order to further delineate the signaling network driving myeloid/endothelial lineage differentiation, we performed gene expression profiling of VEGFR2-expressing hematopoietic progenitor cells (Lin-C-kit+) by mRNA sequencing. Differentially expressed genes from VEGFR2+ versus VEGFR2- HPCs were clustered and arranged in a heatmap. Differentially expressed genes were also clustered and displayed (Figure 17). Candidate genes (P <0.05, >1.5-fold change) were divided according to subsets with the highest expression and analyzed for categories with significant enrichment (P< 0.05) of categories in Gene Ontology (GO) biologic processes using DAVID tools. Similar categories were grouped accordingly (Figure 18). Inhibitor of DNA binding proteins 2 (ID2) was identified as a significantly up-regulated gene in VEGFR2+ HPCs a strong candidate to be an upstream molecule mediating myeloid endothelial differentiation.
Figure 17. RNA-sequencing based gene profiles on KDR+ (VEGFR2) peripheral and bone marrow cells. The heatmap of significantly altered genes in Lin-c-kit+Sca-1- from naïve mice, Lin-c-kit+Sca-1- KDR-GFP+ cells and Lin-c-kit+Sca-1-KDR-GFP- cells from bone marrow of tumor bearing mice.

Figure 18. The candidate genes (P <0.05, >1.5-fold change; Lin-c-kit+Sca-1-KDR(VEGFR2)-GFP+ vs Lin-c-kit+Sca-1-KDR-GFP-) were divided according to the subset with the highest expression and analyzed for categories with significant enrichment (P< 0.05) of categories in Gene Ontology (GO) biologic processes using DAVID tools. Similar categories were grouped accordingly.
To validate the up-regulation of ID2 in HPCs, we performed real-time PCR on KDR\textsuperscript{GFP+} HPCs and Ly6C\textsuperscript{−}/Ly6G\textsuperscript{+} myeloid cells from tumor-bearing or naïve mice. KDR\textsuperscript{GFP+} HPCs from tumor-bearing mice had higher ID2 levels than KDR\textsuperscript{GFP−} HPCs and HPCs from naïve mice (Figure 19). The expression of ID2 was generally lower in myeloid cells than in HPCs. We also examined the expression of ID2 in glioma patients. HPCs were isolated from healthy controls and patients diagnosed with low-grade and high-grade gliomas.
gliomas. HPCs from high-grade glioma patients had significantly higher levels of ID2 than did HPCs from healthy controls and low-grade glioma patients (P<0.0001, Figure 20).

Figure 21. Upstream of KDR (a) the bioinformatic analysis of promoter and 5’-UTR region of KDR by biobase. Highlighted fragment of KDR promoter showed potential binding site for E2A. (b) Chromatin immunoprecipitation of E2A with or w/o over-expression of ID2. Probe on KDR promoter fragments were used. Means ± SEM, **P<0.01, ***P<0.0001 by one way ANOVA. (c) Immunobloting of KDR and ID2 on in vitro cultured Lineage negative bone marrow cells treated with or w/o TGF-β1 and GMCSF. Phospho-smad2/smad2 indicated activation of related signaling. The immunobloting has three replicates.

ID2 functions by inhibiting the binding to DNA of E proteins. To investigate whether ID2 interacted with E proteins to regulate cell fate within the myeloid lineage, we analyzed the promoter region plus the 5’ untranslated region of KDR for putative E protein binding sites known as E boxes. We identified a putative binding site for E2A (Figure 21a) within the upstream promoter region of the KDR gene. To conclusively establish the ID2/E-protein/KDR interaction, we performed a chromatin immunoprecipitation assay using E2A antibody in ID2+/+, ID2 over-expressing, and ID2/-/ bone marrow cells. As expected, antibody to E2A was able to pull down the upstream fragment of KDR. Over-expression of ID2 abolished the binding of E2A to the promoter of the KDR gene (Figure 21b). Although it was beyond the scope and focus of our analysis, our data suggested that soluble GM-CSF and TGF-β may influence the expression of ID2 within pluri-potential bone marrow populations, regulating KDR expression thereby directing cell fate. GM-CSF and TGF-β induced expression of ID2 and KDR in lineage negative bone marrow cells (Figure 21c) similar to conditioned
medium derived from Gl261 cells; blocking either one reversed ID2 and KDR expression. These results support the hypothesis that glioma-secreted GM-CSF and TGF-β initiate pro-tumoral myeloid cell differentiation, directing the formation of the KDR+-pro-angiogenic immune cell population, which plays a crucial role in the tumor microenvironment and malignant glioma transformation.
4. Key Research Accomplishments

I. We have demonstrated that myeloid derived suppressor cells increased following the progression of astrocytic tumor in both patients and murine models.

II. We identified a specific population across endothelial and myeloid lineages, which is VEGFR2+CD11b+ population in patients and tumor bearing mice.

III. We successfully performed knock out VEGFR2 within BMDCs in murine glioma models, and observed that bone marrow derived VEGFR2 contribute to tumor progression and animal survival.

IV. We have performed RNA-sequencing on tumor associated myeloid progenitors, and identified inhibitor of DNA binding proteins 2 was related with pro-tumoral myeloid differentiation.

V. We have demonstrated that ID2 was up-regulated in tumor primed hematopoietic progenitor cells in both patients’ samples and murine models.

VI. We identified the binding region of E2A in VEGFR2 promoter, which indicates role of complex E2A/ID2 in regulation of VEGFR2 expression.
5. Conclusion

In this study, we have utilized glioma patients along with two unique murine glioma models: RCAS glioma model and GL261 model to study the BMDCs during different stages of glial tumor. Importantly, we identified the unique population VEGFR2+MDSCs in both patients and mice, which might be used as a surrogate marker for glioma diagnosis and prognosis in future. We have validated the changes of myeloid lineage and endothelial lineages while the progression of gliomas, and observed the increased population of myeloid derived suppressor cells and endothelial progenitor cells in murine glioma models. We have created inducible VEGFR2 knockout system in glioma bearing mice. Taking advantage of this transgenic model, we demonstrated that bone marrow derived VEGFR2 signaling plays an important role in myeloid differentiation, and infiltration into tumor tissues. Deficiency of VEGFR2 in BMDCs led to impairment of tumor associated myeloid cells and delayed progression of low-grade glioma. All of these findings may help to find the approach to suppress the progression of low-grade glioma into high-grade form, and have implications to predict the long-term survival of glioma patients 13,14.

In the following study, we will keep exploring the various lineages of BMDCs in both low-grade and high-grade glioma patients. We would further validate functional role of VEGFR2+ BMDCs in malignant transformation, and investigate the connection of myeloid differentiation with tumor associated macrophages/neutrophils. We would dedicate our effort to delineate the signaling pathways, which affect pro-tumoral myeloid cells, and further characterize the downstream signaling of inhibitor of DNA binding proteins 2 m(ID2) in BMDCs 15,16. The up-regulation of ID2 in hematopoietic progenitors provided insight how tumor enhances VEGF signaling in pro-tumoral differentiation via ID2/E2A complex.

1) Abstract/Oral presentation


7. Inventions, Patents and Licenses
None

8. Reportable Outcomes
None

9. Other Achievements
None
10. References


11. Training & Professional Development

In the past two years, I have received extensive trainings and related proceedings from various workshops, meetings, and hands-on practices, in addition to regular mentorships from weekly lab meeting and journal club. To follow the frontiers of tumor immunology and tumor microenvironment research, I have attended a workshop on tumor microenvironment (TME) organized by national cancer institute in April 2014. I have communicated with several renowned experts on TME with their study and our proceedings. I also delivered a talk about our work in Cold Spring Harbor-Asia meeting focusing on immunology in diseases, and it was well received. In November 2014, my abstract on protumora myeloid differentiation was selected for oral presentation on Annual Meeting of Society of Neuro-Oncology. Part of my research on PDGF signaling contributed to a publication on Cancer Research in 2014. Additionally, to update my knowledge on biomedical and genomic fields, I have continued courses and workshops including “Genomic workshop”, “Next generation sequencing analysis”, and “Biostatics for Clinical Studies”, which are provided by Clinical Translational Science Center in Weill Cornell Medical College. All the training opportunities armed me for better bench-side research and long-term career development. According to the feedback from my presentations and publications, our work has been well received by scientific community. I am confident to achieve the career goal that I set in the original proposal.
Appendices
Microenvironment and Immunology

Oligodendrocyte Progenitor Cells Promote Neovascularization in Glioma by Disrupting the Blood–Brain Barrier

Yujie Huang1,4, Caitlin Hoffman1,4, Prajwal Rajappa1,4, Joon-Hyung Kim1,4, Wenhao Hu5, Jason Huse5, Zhongshu Tang7, Xuri Li7, Babette Weksler3, Jacqueline Bromberg6, David C. Lyden2,4, and Jeffrey P. Greenfield1,4

Abstract
Enhanced platelet-derived growth factor (PDGF) signaling in glioma drives its development and progression. In this study, we define a unique role for stroma-derived PDGF signaling in maintaining tumor homeostasis within the glioma microenvironment. Large numbers of PDGF receptor-α (PDGFRα)–expressing stromal cells derived from oligodendrocytes progenitor cells (OPC) were discovered at the invasive front of high-grade gliomas, in which they exhibited a unique perivascular distribution. In PDGFRα-deficient host mice, in which orthotopic Gli261 tumors displayed reduced outgrowth, we found that tumor-associated blood vessels displayed smaller lumens and normalized vascular morphology, with tumors in host animals injected with the vascular imaging agent gadolinium also being enhanced less avidly by MRI. Notably, glioma-associated OPC promoted endothelial sprouting and tube formation, in part by abrogating the inhibitory effect that perivascular astrocytes exert on vascular endothelial conjunctions. Stromal-derived PDGF-CC was crucial for the recruitment and activation of OPC, insofar as mice genetically deficient in PDGF-CC phenocopied the glioma/vascular defects observed in PDGFRα-deficient mice. Clinically, we showed that higher levels of PDGF-CC in glioma specimens were associated with more rapid disease recurrence and poorer overall survival. Our findings define a PDGFRα/PDGF-CC signaling axis within the glioma stromal microenvironment that contributes to vascular remodeling and aberrant tumor angiogenesis in the brain. Cancer Res; 74(4); 1011–21. ©2013 AACR.

Introduction
The tumor microenvironment is a complex amalgam of tumor cells, intermingling parenchymal cells, infiltrating immune system cells, and a vascular network of endothelial cells, which in concert determine the pathologic and biological features of distinct tumors. Cancer diagnoses and grades significantly vary the composition of the tumor microenvironment (1–3). Gliomas, malignancies arising from glial cells within the central nervous system (CNS), harbor multiple cell types in addition to cells with tumorigenicity. During normal development (1), tumor cells, intermingling parenchymal cells, in concert determine the pathologic and biological features, and functions of nontransformed glial cells and neural progenitor cells within the natural progression of glioma.

The involvement of platelet-derived growth factor receptor-α (PDGFRα) in gliomagenesis has been well demonstrated (6). Upregulated PDGF signaling through PDGFRα has been found to be a common feature of low-grade astrocytic and oligodendroglial tumors along with a significant subset of glioblastoma multiforme (7, 8). Interestingly, the adult brain contains a widely distributed, abundant progenitor population known as oligodendrocyte precursor cells (OPC), which have been suggested to have high tumor-initiating potential (9–12). These cells identified by expression of NG2/Olig2 are normally cycling oligodendrocyte precursor cells (OPC), which have been suggested to have high tumor-initiating potential (9–12). These cells identified by expression of NG2/Olig2 are normally cycling oligodendrocyte precursor cells (OPC), which have been suggested to have high tumor-initiating potential (9–12). These cells identified by expression of NG2/Olig2 are normally cycling oligodendrocyte precursor cells (OPC), which have been suggested to have high tumor-initiating potential (9–12). These cells identified by expression of NG2/Olig2 are normally cycling

Authors’ Affiliations: 1Department of Neurological Surgery, The Childhood Brain Tumor Project; 2Department of Pediatrics; 3Division of Hematology–Medical Oncology; 4Pediatric Brain Tumor Research, Children’s Cancer and Blood Foundation Laboratories, Weill Cornell Medical College; Departments of 5Pathology and 6Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; and 7National Eye Institute, NIH, Bethesda, Maryland.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Authors: David C. Lyden, 515E 71st Street, New York, NY 10021. Phone: 212-746-3941; Fax: 212-746-8423; E-mail: dcl2016@med.cornell.edu; and Jeffrey P. Greenfield, 525E 68th Street, New York, NY 10065. Phone: 212-746-2363; Fax: 212-746-7729; E-mail: jpgreenf@med.cornell.edu
doi: 10.1158/0008-5472.CAN-13-1072
©2013 American Association for Cancer Research.
Materials and Methods

Cells lines and mice lines

PDGF-C–deficient mice have been previously described (16). C57BL/6-derived glioma cells, GL261 (authenticates as Supplementary Table S1) and KR158, were as described previously (17–19). HCMEC/D3 have been previously described (20; additional information available in Supplementary Methods).

Intracranial injections and tumor imaging

The intracranial injections have been described previously (21). Bioluminescence IVIS-100 (Xenogen) and MRI (Bruker Biospin) were performed to monitor the progression of tumor. Tumor margins in each MRI slice were manually outlined. The area of each region of interest was calculated and then multiplied by the slice thickness. All slice volumes were added up to calculate the volume of each three-dimensional (3D) tumor. For detailed methods, please refer to Supplementary Methods.

Adoptive bone marrow transplantation

Transplantation was carried out as previously described (22) with slight modifications. Recipient mice were lethally irradiated with a single dose of 9.5 Gy to their entire body with their heads shielded. Twenty-four hours after irradiation, 5 × 10^6 total bone marrow cells were injected by tail vein followed by 6 weeks to allow for engraftment of bone marrow cells. The engraftment was confirmed by complete blood count and flow cytometry to ensure adequate hematopoiesis.

Dextran infusion assay

10 mg/mL of 70-kD rhodamine-conjugated Dextran (lysin fixable) was intravenously injected into mice (100 µL/mouse) as previously described (23). Two hours after dextran injection, mice were perfused with 10 mL PBS followed by perfusion of 5 mL of 4% paraformaldehyde. Brain tissue was dissected and fixed for the subsequent staining.

Microarray analysis

Microarray data can be accessed from Gene Expression Omnibus (NCBI/GEO) under accession number GSE38283. For detailed procedures of the preparation of samples, please refer to Supplementary Methods.

Quantification

All data are given as mean ± SD or ± SEM. Differences were compared using Student t tests or one-way ANOVA followed by post hoc tests. For more experimental procedures and quantification details, please refer to Supplementary Methods.

Results

Stromal cells in glioma express PDGFRα

PDGF signaling is upregulated in many patients with glioma: 30% of patients harboring high-grade gliomas express an amplified or mutated PDGFRα gene (7). The infiltration of bone marrow–derived cells (BMDC) is also considered a hallmark of tumor progression (22, 24). To better understand the temporal and spatial variation within the glioma microenvironment of PDGFRα-expressing cells and inflammatory BMDCs, PDGFRα staining was performed on orthotopic GL261 (murine-derived glioma cell line) tumors in mice, which had previously been adoptively transplanted with GFP bone marrow. Large numbers of BMDCs and PDGFRα⁺ cells were identified at the tumor periphery (Fig. 1A). The number of these peritumoral PDGFRα⁺ cells increased at day 14 along with the enhanced infiltration of BMDCs (Fig. 1B). We demonstrated that most PDGFRα⁺ cells, located in the invasive front, were actually nontumor cells. We used orthotopic glioma models with both murine-derived GL261 cells (PDGFRα⁺) constitutively expressing GFP, as well as human-derived U87-MG and U251 cells also expressing GFP (Fig. 1C and Supplementary Fig. S1A), to show that these were not invading tumor cells. Flow cytometry performed upon whole tumor explants confirmed that PDGFRα⁺-expressing cells are GFP negative in all of the GL261, U87-MG, U251, and KR158 glioma models (Fig. 1D and Supplementary Fig. S1). The existence of peritumoral PDGFRα⁺-expressing cells was also verified in the KR158 glioma model (Supplementary Fig. S1D). Western blot analyses showed enhanced expression of PDGFRα in the tumor margin, compared with tissue isolated from the tumor core, the contralateral hemisphere, or from normal age-matched adult mouse brain (Fig. 1E). Immunostaining of PDGFRα showed more PDGFRα⁺ cells in tumor periphery than in the contralateral tissue (Supplementary Fig. S2B). Taken together, these results demonstrate that large numbers of PDGFRα⁺ stromal cells accumulate in the periphery and invade the front of gliomas.

PDGFRα⁺ stromal cells derive from OPC and predominate perivascularly

Different tumors are supported by unique microenvironments containing distinct and specific stromal cell populations. To better define the origin of PDGFRα⁺ stromal cells, we studied the localization of PDGFRα within GL261 tumor specimens using other lineage markers commonly encountered within the glioma microenvironment. PDGFRα⁺ stromal cells did not express markers of neural stem cells (nestin), astrocytes (glial fibrillary acidic protein, GFAP), or endothelium (collagen IV), nor did they colocalize with BMDCs, identified using GFP after GFP⁺ bone marrow transplant (Supplementary Fig. S2). PDGFRα⁺ cells did, however, colocalize with NG2, a marker for OPCs. Moreover, PDGFRα⁺ cells display ramified processes, highly suggestive of OPC morphology, and expressed oligodendroglial lineage marker Olig2 (Fig. 2A and Supplementary Fig. S2C). PDGFRα⁺ glioma-associated OPCs (GA-OPC) can be identified adjacent to vascular endothelium in a sandwich-like configuration (Fig. 2B). Because of permeable features of tumor endothelium and the resolution of microscopy, we did observe limited overlaps between CD31/PDGFRα. The GA-OPCs do not, however, colocalize with pericytes (PDGFRβ⁺) or perivascular astrocytes (GFAP⁺; Fig. 2C and D). In addition to their abundance within the tumor periphery, OPCs also exist within tumor cores with perivascular processes as shown by NG2-DsRed (Supplementary Fig. S2D). NG2 is generally used as OPC maker in CNS, but it also marks certain pericytes and microglial cells.
PDGFRα⁺ stromal cells facilitate the progression and neovascularization of glioma

Tumor cells may educate adjacent nontransformed cells into forming tumor-associated stroma, which can be differentiated from the normal tissue (3, 25). In response to malignancy, OPCs may be activated through PDGFRα signaling (9, 26). To understand the functional role of GA-OPCs in the progression of glial malignancies, we created an orthotopic and syngeneic model using Gl261 cells transfected with a luciferase gene. These cells were implanted in PDGFRα⁻knockout mice to study the importance of PDGFRα signaling between stromal and tumors cell populations, upon glioma progression. In Rosa-cre/PDGFRα⁻/⁻ mice, growth of Gl261 tumors was inhibited compared with tumor growth in Rosa-cre/PDGFRα⁺/⁺ mice (Fig. 3A). MRI analysis of Gl261 tumors in PDGFRα⁻/⁻ mice demonstrated animals with less tumor burden and tumors with less contrast enhancement on MRI than tumors within control mice (Fig. 3B). Compared with tumors in PDGFRα⁺/⁺ mice, tumors in PDGFRα⁻/⁻ mice had a slightly higher blood vessel density (Supplementary Fig. S3A) and demonstrated distinct vascular morphology. Gliomas within PDGFRα⁻/⁻ mice demonstrated considerably smaller diameters of vessel lumens (Fig. 3C), similar to vasculature typical within the normal mouse brain. Importantly, within PDGFRα⁻/⁻ mouse tumors, pericyte density and architecture was not significantly changed from PDGFRα⁺/⁺ mice as visualized by the staining for PDGFRβ (Supplementary Fig. S3B).

Neovascularization of gliomas is distinct from other types of tumors. Perhaps due to the brain's robust vascular network, brain tumors either remodel preexisting blood vessels or recruit endothelial progenitor cells to undergo microvascular proliferation, a hallmark of high-grade gliomas (1, 27).
Compared with normal brain and low-grade gliomas, grade III and IV gliomas have distorted, enlarged blood vessels but do not necessarily demonstrate higher blood vessel density (27). Blood vessels in high-grade gliomas are distinguishable from those in low-grade gliomas not by their density, but by their morphology. In PDGFRα−/− mice, Gl261 brain tumor–associated blood vessels were not enlarged or distorted compared with that within tumors in wild-type mice. Tumor cells in PDGFRα−/− mice have less mitotic activity (decreased Ki67 staining), less hypoxia demonstrated (decreased pimonidazole staining), and less leakiness as indicated by a dextran infusion assay (Supplementary Fig. S3C). Other factors, which could theoretically induce changes in vascular morphology, were studied in both groups of animals by measuring the infiltration of BMDCs and monitoring hematopoiesis; there were moderate decreases of infiltrating BMDCs within Gl261 tumors in PDGFRα−/− mice (Supplementary Fig. S4A), and hematopoiesis does not appear to be affected (Supplementary Fig. S4B).

**GA-OPCs facilitate angiogenesis**

To better understand the contribution of GA-OPCs to the vascular remodeling occurring during glioma neovascularization, we performed *in vitro* assays using primary GA-OPCs cultures. Primary human-derived GA-OPCs and glioma cells were isolated directly from glioma resections (Supplementary Fig. S5A); OPCs were maintained in the progenitor stage within the oligodendritic lineage (Supplementary Fig. S5B and S5C). Using a 3D culture system, we cocultured human brain endothelial cells (HCMEC/D3) with GA-OPCs or human astrocytes, or both, to study their interactions. We labeled the HCMEC/D3

![Figure 2. OPC-derived PDGFRα stromal cells are perivascular. A, PDGFRα (red) colocalizes with NG2 (green) in the tumor periphery. Arrow, overlap. Asterisk, NG2− cells (green) with suggestive pericyte morphology. Scale bar, 50 μm. B, PDGFRα is adjacent to blood vessel marker CD31 and is not colocalized with the pericyte marker PDGFRβ (C). Z-stack imaging was used with confocal microscopy. Scale bar, 20 μm. D, costaining of GFAP (perivascular astrocytes) and PDGFRβ (pericytes) on Gl261 tumor periphery. Arrows, vascular lumens; scale bar, 20 μm.](Image)
cells with GFP and allowed them to form tubules. Once a tubule network was established, equal numbers of GA-OPCs and astrocytes were introduced to the endothelial cell cultures. The in vitro 3D coculture system recapitulated the in vivo phenomenon within which the astrocytic foot processes surround endothelium to form the blood–brain barrier. We found that both astrocytes and GA-OPCs were adjacent to the endothelial tubules. Astrocytic foot processes formed an intact and continuous tubule-like structure close to endothelial tubules. In contrast, GA-OPCs appeared to integrate with the endothelial tubules but did not form continuous intercellular interaction with each other as did astrocytes (Fig. 4A). Interestingly, if we allowed astrocytes to establish interaction with HCMEC/D3 first with coculture, and then added GA-OPCs, the GA-OPCs could disrupt the interaction formed between astrocytes (Fig. 4A). We further used in vitro models to test the permeability of these intercellular interactions, which were formed by endothelial cells under differing coculture conditions. These assays demonstrated that astrocytes protect the integrity of the endothelial cell monolayer while bathed in U251 cell–derived conditioned medium, whereas GA-OPCs abrogate the protective effect of astrocytes by creating a more permeable endothelial cell monolayer (Supplementary Fig. S6C).

In addition to defining interactions between endothelial cells, astrocytes, and GA-OPCs, we performed a series of angiogenesis assays to study the mechanism through which GA-OPCs impact vascular remodeling. We used a sprouting assay to investigate the influence of perivascular stromal cells upon the migration of endothelial cells. Astrocytes suppressed sprouting from endothelial spheres made from HCMEC/D3; GA-OPCs reversed this inhibitory effect when cocultured with astrocytes (Fig. 4B). We also analyzed the number of endothelial cells in coculture with astrocytes and GA-OPCs. Both astrocytes and GA-OPCs only minimally affected the number of endothelial cells (Supplementary Fig. S5D), suggesting that the regulatory effect of stromal cells on endothelial sprouting was proliferation independent. This function is PDGFRα dependent; a neutralizing PDGFRα-specific antibody reversed the effect (Supplementary Fig. S6A). Tubule formation assays similarly demonstrated that astrocytes inhibited the formation of new endothelial tubules and GA-OPCs reversed this in a PDGFRα signaling–dependent manner (Fig. 4C and Supplementary Fig. S6B).

How these interactions between endothelial cells and OPCs directly affect the tumor progression is difficult to precisely define. We have demonstrated that inhibiting OPCs clearly affects angiogenesis, which might then inhibit tumor progression. More interestingly, there may also exist a direct link between endothelial and tumor cells. We hypothesized that OPCs may direct endothelial cells into a more active state through upregulation of angiocrine factors, thereby promoting malignancy. We cocultured endothelial cells with Gl261 cells in the presence or absence of VEGF (to stimulate endothelial cells). We found that tumor cells proliferated more when cocultured with activated endothelial cells than when cocultured with normal endothelial cells (Supplementary Fig. S7).

Considering the complex nature of the glioma microenvironment, interaction between OPCs and endothelial cells may be
even more complicated than that hypothesized with multiple pathways independently promoting malignancy.

**BMDCs and stromal-derived PDGF-CC are key mediators to GA-OPCs**

In the context of the glioma microenvironment, OPCs exponentially increase in number and in the expression of PDGFRα (Fig. 1). Signaling that originates from tumor-initiating or alternative stromal cells might trigger OPC activation and redirect them into protumoral phenotypes. As described above, the number of PDGFRα⁺ cells dramatically increased around day 14 after injection of tumor cells, which mirrored the pattern of immune cell infiltration (Fig. 1A and B). Therefore, we sought to test the hypothesis that infiltrating BMDCs contribute to the recruitment and activation of GA-OPCs during tumor progression. In addition, BMDCs are detected not only intratumorally, but also within the tumor periphery (Fig. 1A), a localization that would...
permits direct BMDCs/GA-OPCs interactions. Subsequently, we further characterized the infiltrating GFP⁺ BMDCs in Gl261-implemented mice, and found that more than 80% of the BMDCs in these tumors are F4/80⁺ macrophages/microglial cells (Supplementary Fig. S8A). We then performed microarray analysis on GFP⁺/F4/80⁺ BMDCs, and found that the PDGF-C gene was significantly upregulated in glioma-associated BMDCs compared with BMDCs from normal murine brain (Supplementary Fig. S8B). PDGF-C is a cytokine that preferentially homodimerizes into PDGF-CC, which is the ligand predominantly binding PDGFRα. The upregulation of PDGF-C in bone marrow–derived macrophage/microglia isolated from murine gliomas was confirmed by real-time PCR (RT-PCR; Fig. 5A).

**PDGF-C deletion recapitulates PDGFRα null phenotype**

To examine whether PDGF-CC derived from bone marrow–derived macrophages or microglial cells might push GA-OPCs into tumor-supporting phenotypes, we transplanted wild type C57BL/6 mice with bone marrow from PDGF-C⁻/⁻ donor mice. Six weeks after bone marrow engraftment, luciferase-labeled Gl261 cells were injected intracranially into recipient mice. PDGF-C⁻/⁻ mice did not show any developmental defects in their hematopoietic system (Supplementary Fig. S9); however, we found that tumors implanted within mice transplanted with PDGF-C⁻/⁻ bone marrow grew more slowly at an early stage of tumorigenesis (day 14) than tumors in mice transplanted with littermate PDGF-C⁺/+ bone marrow. However, in later stages (day 21) of tumor growth, PDGF-C⁻/⁻ bone marrow–transplanted animals no longer demonstrated a statistically significant reduction of tumor size (Fig. 5B). Within the tumor periphery specifically, we found significantly fewer PDGFRα⁺ cells in the PDGF-C⁻/⁻ bone marrow–transplanted group at D14 (P = 0.0051), but not at a later stage (D21; P = 0.32; Fig. 5C). These results suggest that microglia-derived PDGF-CC did contribute to the recruitment and activation of GA-OPCs, a process not necessarily dependent upon bone marrow–derived macrophages/microglia at later stages of tumor development.

Soluble PDGF-CC may not be solely secreted by BMDCs; thus, we inferred that other stromal cells within the glioma microenvironment such as resident microglia, activated astrocytes, or angiogenic endothelial cells could be candidates as sources of soluble PDGF-CC. Therefore, we tested PDGF-C expression in astrocytes and endothelial cells in response to tumor cells. Primary cultures of astrocytes and endothelial
cells were isolated from mouse brain, and treated with or without conditioned medium derived from Gl261 cell culture. RT-PCR from both primary cultures showed that the expression of PDGF-C was upregulated by tumor-conditioned medium (Fig. 5D), implying that PDGF-CC might be expressed and secreted by glioma-associated astrocytes and endothelial cells. However, we found that other types of tumor cells, including B16/F10 and KR158, could both upregulate the PDGF-C expression within stromal cells (Supplementary Fig. S10A), suggesting that the upregulation of PDGF-C may be specific to glioma stroma, but not to tumor cells. The stromal-derived PDGF-CC may also be related to other cancers and proinflammatory states.

To assess the contribution of total stromal PDGF-CC to gliomagenesis, we intracranially injected Gl261 cells into PDGF-C−/− knockout mice. Gl261 tumor growth in PDGF-C−/− mice was significantly slower, and tumor burden was less than the tumors in littermate PDGF-C+/− mice (Fig. 6A and B). MRI demonstrated strikingly less tumor enhancement in PDGF-C−/− mice. These results recapitulated the phenotype of Gl261 tumor progression in PDGFRα−/− knockout mice. More importantly, we found many fewer PDGFRα− cells in the tumor periphery in PDGF-C−/− mice and significantly smaller vascular lumens (Fig. 6C). Taken together, these results demonstrate that stromal-derived PDGF-CC is a key mediator in the recruitment and activation of OPCs during the progression of gliomas.

PDGF-CC, of which the primary receptor is PDGFRα, has been implicated in various cell types and pathologic conditions. A recent study showed that PDGF-CC knockout mice showed abnormal cerebral vascularization (28), supporting the role of PDGF-CC in regulating the vascular architecture under physiologic conditions in the CNS. In the postnatal brain, PDGFRα is exclusively expressed on OPCs (29). Thus, the stromal PDGF-CC/PDGFRα axis may be an important intrinsic angiogenic signaling pathway regulating angiogenesis in gliomas—indeed, independent of the classic VEGF-mediated pathway. To further understand the role of this signaling axis in regulating angiogenesis, we used an angiogenesis antibody array (R&D systems) to profile the angiogenic factors derived from OPCs after the exposure to PDGF-CC. PDGF-CC upregulated proangiogenic factors such as CXCL10, CX3CL1, and IGFBP-1 in the PDGF-CC+ group and the PDGF-CC− group. Scale bar, 50 μm. Means ± SD, n = 5 mice; t test, **, P < 0.01.

Figure 6. Glioma growth in PDGF-C deficient mice is phenotypically similar to glioma growth in PDGFRα KO mice. A, growth of orthotopic Gl261 tumors in PDGF-C+/− and PDGF-C−/− mice. Tumor burden is represented by bioluminescence photon flux. Means ± SD, n = 6 mice; t test, **, P < 0.01. B, pre- and post-contrast T1-weighted MRI was used to image Gl261 tumors in PDGF-C+/− animals and PDGF-C−/− animals on day 17. Arrows, the enhancing tumor region. Tumor volumes were quantified. Means ± SD, n = 5 mice; t test, **, P < 0.01. C, PDGFRα− cells were decreased in PDGF-C−/− mice. Blood vessels (collagen IV) and PDGFRα were stained in both the invasive tumor front (invasive front) and from within Gl261 tumors (intratumor) grown in the PDGF-C+/− and PDGF-C−/− group. Scale bar, 50 μm. Means ± SD, n = 5 mice; t test, ***, P < 0.001.
GA-OPCs in patients with glioma

The brain tumor microenvironment in patients with glioma is very complex. The signaling within undefined stromal populations and tumor cells is intricate. This is further complicated by the molecular heterogeneity between subpopulations of actual glial tumor cells. Therefore, we sought to confirm and quantify the existence of PDGFRα+ stromal cells directly from samples resected from patients diagnosed with a high-grade glioma. Among established markers for glioma cells, isocitrate dehydrogenase 1 (IDH1) mutation is extremely reliable in distinguishing tumor cells from stromal cells as it has been used to detect even single disseminated tumor cells (30, 31). Grade III astrocytomas bearing IDH1 mutations were chosen, and stromal cells were characterized as negative for the IDH mutation. Doubly staining for PDGFRα and IDH (R231H), we demonstrated a population of cells positive for PDGFRα and negative for IDH (R231H; Fig. 7A). Interestingly, this region was actively undergoing microvascular proliferation evidenced by enlarged vascular lumens (Supplementary Fig. S11).

As we demonstrated in our animal glioma models, PDGF-CC is a potential ligand through which the activation of GA-OPCs may occur, thereby contributing to angiogenesis and glioma progression. In PDGF-C null mice, glioma progression was slowed due to a lack of activated GA-OPCs. We examined the expression of PDGF-C in different types of gliomas within Rembrandt. We observed that expression levels of PDGF-C were higher in high-grade gliomas as compared with low-grade gliomas or nontumor diseases (Supplementary Fig. S12). To further study the role of PDGF-CC in human high-grade gliomas, data from The Cancer Genome Atlas (TCGA) for different subsets of patients with glioblastoma were analyzed based on their expression of PDGF-C. Samples were subgrouped into those with higher PDGF-C expression (top 10–14%) with the remainder classified as PDGF-C low. Analyses of survival and progression were performed within four recognized subsets of glioblastoma, including classic, proneural, mesenchymal, and neural. Within the classic subset of glioblastoma, but not in other subsets, expression of PDGF-C was significantly correlated with disease progression ($P = 0.0060$), and inversely correlated with survival of patients ($P = 0.0081$; Fig. 7B and Supplementary Fig. S13). This demonstration within the classic subset of human glioblastoma is consistent with our demonstrated slowing of orthotopic Gl261 tumor progression in PDGD-C null mice. Surprisingly, even other members of the PDGF family, including PDGF-A and PDGF-B, commonly upregulated in glioblastoma, were not found to be statistically significantly ($P > 0.05$) correlated with patients’ survival or disease progression (Supplementary Fig. S14).

Discussion

OPCs are the most abundant neural progenitor cells in postnatal brains. They can differentiate into oligodendrocytes or astrocytes in response to different stimuli to aid in myelination and wound healing, among other roles in the CNS (32–36). Recent studies also suggest that OPCs have a higher degree of plasticity and may be more sensitive to transformation (9, 10). In certain rodent brain tumor models, it has been demonstrated that recruited stromal OPCs can be tumorigenic. However, their transformation of OPCs may require a preexisting oncogenic mutation such as Ink4a/Arf or P53 as indicated by these studies (37).
Invasive glioma cells frequently migrate along myelinated white matter fiber tracts (38), a phenomenon whose underlying mechanism is not clearly elucidated. It has also been established that OPCs preferentially reside along identical pathways of dissemination (39, 40). Many studies have examined and demonstrated that glioma progression and invasion follows a perivascular pattern (25, 41, 42), particularly at disease recurrence. In this study, we demonstrated angiogenic endothelial cells, perivascular macrophages/microglia, and OPCs working in concert to form a proangiogenic and proinvasive niche at the invading front of glioma. Our data suggest that stromal OPCs are a key element not only in initiating angiogenesis but also in driving glioma invasion. To extend our hypotheses derived from mouse models to humans, we selected IDH1R132H mutant grade III astrocytomas within which to analyze stromal PDGFRα+ cells from human specimens. The IDH1 R132H mutation is an ideal marker to distinguish between tumor cells and stromal cells in grade III astrocytomas. In addition, grade III astrocytomas are by definition in the transition stage, during which we suggest that OPCs play a crucial role in both microvascular proliferation and tumor invasion.

In the previous work, PDGF-CC was found to induce the loss of the blood–brain barrier and induce vascular leakiness in a stroke model, and PDGF-C deficiency leads to abnormal cerebral vascularization (28, 43). In our study in tumor-bearing mice, the number of OPCs with activated PDGFRα+ was increased compared with non–tumor-bearing mice. However, similar tumors could not increase the number of OPCs in PDGF-C–/– mice. Interestingly, PDGF-CC has been identified as a key factor allowing tumors to recur following the anti-VEGF treatment in glioblastoma and other types of cancer (44, 45). All of this evidence suggests that PDGF-CC plays an important role in the vascular remodeling occurring in gliomas, which may be independent of the classic VEGF pathway. When studying survival using the glioblastoma cohort in TCGA, we demonstrated a survival advantage correlating with the PDGF-C expression only in the classic subgroup of glioblastoma. We hypothesize that the correlation within the classic subgroup might be due to differences of the origin of tumor cells between the subgroups of glioblastoma. Mesenchymal, or proneural subtypes may be derived directly from OPCs where it has been suggested that tumor cells may inherit certain features directly from OPCs. In this class of glioblastoma, the tumor cells may overshadow stromal OPCs with respect to their proangiogenic role. Recent studies have demonstrated that tumor cells may transdifferentiate into endothelial cells and pericytes (46–48). This finding suggests that tumor heterogeneity along with the complex nature of the tumor microenvironment can result in the utilization of multiple angiogenic pathways.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Y. Huang, D. Lyden, J.P. Greenfield
Development of methodology: Y. Huang, B. Weksler
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Huang, C. Hoffman, P. Rajappa, J.-H. Kim
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Huang, P. Rajappa, J.-H. Kim, W. Hu, J. Bromberg, J.P. Greenfield
Writing, review, and/or revision of the manuscript: Y. Huang, C. Hoffman, P. Rajappa, J.-H. Kim, J.T. Huse, Z. Tang, X. Li, B. Weksler, J. Bromberg, D. Lyden, J.P. Greenfield
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.T. Huse, Z. Tang, X. Li
Study supervision: D. Lyden, J.P. Greenfield

Acknowledgments
The authors thank Dr. Irina Matei for manuscript editing, Drs. Tyler Jacks and Karlyne Reilly for providing KR158 cells, Dr. David Zaggag for providing G261 cells, Scott Kerns for imaging assistance, and Eric Aronowitz for MRI assistance.

Grant Support
This study was supported by DoD DCDARP (CA120318), Elizabeth’s Hope, and The Matthew Larson Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 15, 2013; revised December 2, 2013; accepted December 6, 2013; published OnlineFirst December 26, 2013.

References
Oligodendrocyte Progenitors Promote Glioma Angiogenesis


